Exousia Pro Accelerates Telehealth Expansion with Third Acquisition

Biotechnology firm secures new distribution channels for cancer tests and nutraceuticals

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Exousia Pro, Inc., a clinical-stage biotechnology company, has announced the execution of a third Letter of Intent (LOI) to acquire an established telehealth organization. This latest acquisition represents a key part of Exousia's strategy to build a vertically integrated health ecosystem, providing the company with independent revenue streams and immediate access to a vast network of patients and providers. By marketing its proprietary cancer screening tests and nutraceutical products directly through its own telehealth channels, Exousia expects to achieve a lower customer acquisition cost and drive higher margins.

Why it matters

The acquisition of established telehealth platforms allows Exousia to secure a high-efficiency distribution channel for its proprietary clinical products, reducing customer acquisition costs and accelerating market penetration. This vertical integration strategy aims to bridge the gap between Exousia's clinical innovations and patient access.

The details

The latest target organization operates within a prestigious niche, partnering with university-connected hospitals across the United States. This company utilizes a proprietary model that can reduce hospital prescription costs by up to 50%, with Exousia typically receiving 10% of the total savings generated for the hospital over a four-year period. The majority of commissions are realized within the first two years, followed by recurring residual payments, providing Exousia with robust, predictable cash flow.

  • Exousia originally aimed to execute definitive agreements for the initial two acquisitions by the end of January 2026.
  • The execution date has been moved to later this month due to the depth of the audit-ready verification process.

The players

Exousia Pro, Inc.

A clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems.

Matt Dwyer

The President of Exousia Pro, Inc.

Got photos? Submit your photos here. ›

What they’re saying

“We are aggressively scaling our healthcare infrastructure through these targeted acquisitions. Beyond the significant standalone revenue these entities generate, they provide us with a captive, high-intent audience. This allows us to deliver our cutting-edge cancer screening tests and nutraceuticals directly to patients at a fraction of the usual marketing cost. We are building a self-sustaining cycle of clinical innovation and efficient commercialization.”

— Matt Dwyer, President (Exousia Pro, Inc.)

What’s next

Management is currently finalizing the extensive due diligence process for the initial two acquisitions, with the execution of definitive agreements expected later this month.

The takeaway

Exousia Pro's strategic expansion into telehealth allows the company to leverage its clinical innovations and deliver its proprietary products directly to patients at a lower cost, creating a sustainable model that bridges the gap between medical breakthroughs and patient access.